2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - 260-262
Access, Representation, Population Health, Treatment Considerations, Adverse Events, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Young Adult
PAPER

461 Early palliative care integration and healthcare utilization in patients with newly diagnosed multiple myeloma: A matched cohort pilot study

Renato Verayo Samala, MD, MHPE, Wei Wei, MS2, Faiz Anwer, MD3, Beth Faiman, PhD, MSN, APN-BC, AOCN®, TCTCN®, FAAN, FAPO4, Shahzad Raza, MD5, Paul Nurse, DO, MS6, Ruth Lagman, MD, MPH, MBA7, Jack Khouri, MD8, Sandra Mazzoni9, Christy Samaras, DO10, Louis Samuel Williams, MD11, Jason Valent, MD12
1 Cleveland Clinic, Cleveland, Ohio, United States
2 Cleveland Clinic, Cleveland, Ohio, United States
3 Cleveland Clinic, Cleveland, Ohio, United States
4 Cleveland Clinic, Cleveland, Ohio, United States
5 Cleveland Clinic, Cleveland, Ohio, United States
6 Cleveland Clinic, Cleveland, Ohio, United States
7 Cleveland Clinic, Cleveland, Ohio, United States
8 Cleveland Clinic, Cleveland, Ohio, United States
9 Cleveland Clinic, Cleveland, Ohio, United States
10 Cleveland Clinic, Cleveland, Ohio, United States
11 Cleveland Clinic, Cleveland, Ohio, United States
12 Cleveland Clinic, Cleveland, Ohio, United States

Introduction: The symptom burden experienced by patients with multiple myeloma (MM) can be quite profound due to its incurable nature and cumulative toxicity from multiple lines of treatment. Managing symptoms and complications will inevitably require the use of healthcare resources. Early integration of palliative care (PC) in treating patients with solid tumors have been shown to reduce healthcare utilization and costs, especially towards the end of life. It remains unknown whether the same effect is seen in patients with MM. In our previous study, patients enrolled within eight weeks of diagnosis received regular PC outpatient visits consisting of comprehensive assessment and management of pain and other symptoms caused by MM and its treatment, as well as advance care planning and psychosocial support. We observed that functional well-being, pain experience, and overall quality of life improved following monthly PC visits for a year. In this follow-up study, we compared this cohort to a propensity score-matched group of patients with newly diagnosed MM, who received standard care, to determine the effects of early PC on healthcare utilization.

Methods: Patients were enrolled in our original study from January 2020 to November 2022. The control group was selected from all adult patients diagnosed with symptomatic multiple myeloma at our institution’s cancer center from January 2020 through December 2023. Using propensity score-matching, control patients were identified by age, gender, and Eastern Cooperative Oncology Group (ECOG) score using a 1:2 ratio. Outcome measures included number of emergency room (ER) visits, number of unplanned hospital and intensive care unit (ICU) admissions, and number of days spent in the hospital and ICU. Data were collected within one year from the time of diagnosis. This single-center pilot study was approved by Cleveland Clinic’s Institutional Review Board.

Results: Median age (range) was 65 (40 to 77) for the case group (n = 20) and 64 (38 to 86) for the control group (n = 40). In both groups, 75% were female and 55% had an ECOG score of 1. Glomerular filtration rate was 60 or higher for 60% of case and 73% of control patients. Bone involvement at time of MM diagnosis was seen in 75% of case and 65% of control patients. Case group had a median (IQR) of 0 (0-0.5) ER visits, 1.5 (0-11.5) unplanned hospital days, and 0 (0-0.5) ICU days. Control group recorded 0 (0-1) ER visits, 0 (0-10) unplanned hospital days, and 0 (0-0) ICU days. Looking at the cumulative number of ER visits across 12 months, the case group had 2 (10%) at three months, 3 (15%) at six months, and 5 (25%) at 12 months, compared to 6 (15%) at three months, 12 (30%) at six months, and 14 (35%) at 12 months for the control group. There were no other differences in unplanned hospital admissions, ICU admissions, hospital days, and ICU days between the two groups.

Conclusion: In this pilot study of patients with newly diagnosed MM, the early PC group appeared to have experienced fewer ER visits in the first 12 months following diagnosis compared to patients who received standard care. PC integration did not appear to differ from standard care in terms of hospital and ICU admissions. The enrollment window for the case group and the selection period for control patients occurred during the COVID-19 pandemic, which may have affected both arms and contributed to our findings. Circumstances that prompt extensive healthcare use, such as acute infections and circulatory collapse, could not have been averted by PC use. Future studies could look at actual healthcare costs associated with PC involvement in patients with MM, and should examine patients further along the MM trajectory, such as those with relapsed or progressive disease.

 

Renato Verayo Samala, MD, MHPE: No relevant conflicts of interest to declare.